TOKENPOST
1 min read
Add as a preferred source on Google

Revelation Biosciences Posts $5.92 GAAP Loss Per Share in Q3 2026

Cash and cash equivalents were $9.1 million on Sept. 30, 2026, compared with $10.7 million on Dec. 31, 2025.

By John Kim
Published
A laboratory vial stands beside a single folded blank banknote. / TokenPost.ai
A laboratory vial stands beside a single folded blank banknote. / TokenPost.ai

Revelation Biosciences, Inc. (REVB) posted a GAAP loss of $5.92 per share for the third quarter of 2026. The company had $9.1 million in cash and cash equivalents at quarter-end.

Cash and cash equivalents totaled $9.1 million as of Sept. 30, 2026, compared with $10.7 million on Dec. 31, 2025.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…